NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) — Betty’s Eddies^TM announced today a collaboration with the Keep A Breast (KAB) Foundation to advance breast cancer awareness education and support the millions of people affected by the disease. The initiative includes redesigned product packaging and a campaign to foster KAB’s mission of reducing breast cancer risk through education, with a focus on early detection. Betty’s Eddies parent company, MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), will also make a monetary donation to KAB. The month-long campaign coincides with Breast Cancer Awareness Month in October.

The all natural, cannabis fruit chews brand, handcrafted to suit a variety of specific end effects, has launched a limited time redesigned pink package for its fan-favorite Ache Away Eddies ’s that highlights KAB’s mission of reducing breast cancer risk through education. The cherry-flavored chews, infused with CBD, CBC and THC, plus turmeric, piperine and vitamin E may help ease inflammation and aid recovery.

Both MariMed and Betty’s Eddies will bolster the partnership, which aligns with both brand’s deep commitment to health and wellness, by promoting the KAB app on the redesigned packaging and on their social media channels. The app, available on the Apple and Google Play Stores, offers education about and advocacy for self-checking and immediately connects users to medical professionals when necessary. A limited number of Betty’s Loves Boobies bracelets, designed especially for this partnership, will be distributed for free at select dispensary locations while supplies last.

“Every day, we hear from patients about how Betty’s Eddies helped them throughout their treatment journey,” Sara Rosenfield, Betty’s Eddies Brand Manager, said. “Our partnership with the Keep A Breast Foundation honors those battling breast cancer and empowers people to pay attention to their health, including prevention and early detection.”

Customers in Massachusetts, Maryland and Delaware can participate in the Ache Away Betty’s collaboration by purchasing the product in licensed dispensaries and by downloading the KAB app that promotes access to care.

“When the Betty’s Eddies team approached us with this partnership idea, we were excited to reach even more people and encourage early detection,” Shaney Jo Darden, Founder of Keep A Breast Foundation, said. “With recent research indicating the potential for cannabis to alleviate the painful side effects of cancer treatment, we saw this as the perfect partnership in support of our mission.”

KAB x Ache Away Betty’s Chews will be available while supplies last in October.

Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

Investor Relations Contact:
Steve West
Vice President, Investor Relations
Email: ir@marimedinc.com
Phone: (781) 277-0007

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

DELTA, British Columbia, April 20, 2022 (GLOBE NEWSWIRE) — Today, on 4/20, BC-based cannabis producer Pure Sunfarms launches Pure Sunfarms FLOWERHOOD, a collaborative project featuring six artists bringing to life the stories of its flower through iconic artwork. The designs of each artist are thoughtfully applied to hand-selected vintage garments to create the one-of-a-kind FLOWERHOOD collection.

The project brings to life the story of Pure Sunfarms signature strains through the eyes of Laura Garcia Serventi (Brooklyn, USA), Mia Ohki (Vancouver, Canada), Dan Climan (Montreal, Canada), Studio A-OK (Vancouver, Canada), Lan Truong (Portland, USA), and Ana Miminoshvili (Tbilisi, Georgia). The custom artwork created by each artist is rooted in the rich history of the strain and the anatomy of the plant itself, interpreted in their own style. The work expresses what each artist sees in the cannabis plant through hand-drawn and digital illustrations, paintings, and premium patchwork.

The Pure Sunfarms FLOWERHOOD collection will be available exclusively on Pure Sunfarms Marketplace starting May 6, 2022, including a hand-painted denim jacket, screen-printed tees, and embroidered French chore coats.

“Pure Sunfarms is built on a foundation of putting plants and people first,” says Maria Guest, Vice President of Brand, Pure Sunfarms. “For Pure Sunfarms FLOWERHOOD, we set out to create something meaningful to reflect the connection between the two. With our flower and greenhouse at the heart of it all, we brought together a group of inspiring artists to interpret our BC-grown strains in their own unique style. We’re excited to share this collaboration and for cannabis consumers to experience FLOWERHOOD.”

“It’s fascinating how unique the plant can be from strain to strain,” says Laura Garcia Serventi, Brooklyn-based botanical artist. Laura has been working with Pure Sunfarms since the brand’s inception as its most featured artist. “Over the years of working with Pure Sunfarms, I’ve really fallen in love with the details of the plant’s anatomy, and also the origin story of each strain. It’s such a rich plant in every way, and I love that my partnership with Pure Sunfarms gives me the freedom to express these details in my own hand-painted style.”

To learn more about Pure Sunfarms FLOWERHOOD, browse the limited collection, and view the exclusive docu-series capturing the artist collaborations, visit: puresunfarms.com/flowerhood

People looking to receive updates about the collection sales launch can sign-up by visiting puresunfarms.com/subscribe and by following @PureSunfarms on Instagram. Must be 19+.

For more information about Pure Sunfarms, visit www.puresunfarms.com

​About Pure Sunfarms

Pure Sunfarms is one of the largest cannabis operations in the world, producing high-quality, BC-grown cannabis in 1.65 million square feet of greenhouse space in Delta, British Columbia. The company brings together decades of agricultural and legacy cultivation experience with best-in-class, large scale operational expertise, and is one of Canada’s top-selling brands.

The company has capacity to produce, sell, and distribute 112,500 kilograms of dried flower annually for Canadian recreational and international markets. Pure Sunfarms is currently converting a second greenhouse for cannabis production, which when complete is expected to bring annual output capacity to 150,000 kilograms.

Current supply agreements include the Ontario Cannabis Retail Corporation (OCRC) (operating as the Ontario Cannabis Store (OCS)), the BC Liquor Distribution Branch (BCLDB), Alberta Gaming, Liquor & Cannabis (AGLC), the Saskatchewan Liquor and Gaming Authority (SLGA), and the Manitoba Liquor and Lotteries Corporation. Pure Sunfarms also provides cannabis to other Licensed Producers in Canada, including its affiliate ROSE LifeScience in Québec. The company also has EU GMP certification.

Pure Sunfarms is the wholly-owned Canadian subsidiary of Village Farms International, Inc. (Nasdaq: VFF).

www.puresunfarms.com

Media Contact
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, has entered into a strategic business development agreement with AB Strategic Ventures (“ABSV”) with the purpose of supporting relationship building with First Nations business enterprises through the fulfillment and sale of products made by Indigenous people to markets across Canada. Additionally, the agreement will support product development, branding, marketing and sales in partnership with Indigenous peoples and their respective communities to ensure cultural authenticity and appropriate positioning.

“We are pleased to partner with Indigenous peoples and businesses in building mutually beneficial relationships that will fuel their growth and nurture their economic visions,” said Mark Upsdell, CEO Rapid Dose Therapeutics. “This partnership with ABSV will assist us on our journey of understanding while appreciating the cultural values that will lead to thoughtful and meaningful collaborations all across Canada.”

ABSV works directly with Indigenous communities to promote economic and capacity development with a focus on increasing their own-source revenue streams. ABSV has raised capital, developed business and marketing plans, and has led community consultations with the private sector to custom tailor cooperation agreements that benefit all. Working with First Nations in every province and territory of Canada, ABSV has worked with more than 100 Indigenous communities throughout Canada to support the development of their economies.

“RDT has demonstrated a commitment to champion Indigenous business enterprises and we’re pleased to assist them in bringing broad-scale awareness to First Nations across Canada,” said Arnold Bomberry of AB Strategic Ventures. “Inclusivity is a much-needed approach in today’s landscape and we look forward to the opportunities that bring communities together.”

Initial product collaboration will include both RDT and private label branded products in the lifestyle, health and wellness sectors, including vitamins, nutraceuticals and topicals.

ABSV agrees to provide ongoing advisory services to RDT for an initial period of two years.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

www.rapid-dose.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Toronto, Ontario–(Newsfile Corp. – August 25, 2021) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into a Clinical Trial Agreement with The Johns Hopkins University (JHU) to conduct a clinical study comparing acute and enduring psychological and neural effects of N,N-Dimethyltryptamine (DMT) and an undisclosed, potently active comparator molecule. The principal investigator, Dr. Frederick S. Barrett, PhD, Associate Professor of Psychiatry and Behavioral Sciences, will be supported by Co-investigators Dr. Sandeep Nayak and Dr. Roland Griffiths; all from the JHU Center for Psychedelic and Consciousness Research.

The potential of psychedelic drugs to treat various neuropsychiatric indications is currently being explored in several human clinical trials. The dramatic mind-altering effects of these drugs is well known, and as such, a study volunteer’s expectancy may contribute to clinical outcomes. Such effects are considered classic study confounds and can lead to misinterpretation of efficacy signals. For example, this phenomenon was recently noted in a large, placebo-controlled study of LSD which found that those receiving LSD or placebo showed significant improvements in mood, anxiety, creativity and energy¹. To address this common study design limitation and to assess the neuropsychiatric impact of DMT more fully, the Company has sponsored the submission of an Investigational New Drug (“IND”) application to the U.S Food and Drug Administration (“FDA”) which aims to compare the effects of DMT with another potently psychotropic drug.

The first part of the planned study will examine dose effects of DMT and the other test article. During the second part of the study, healthy subjects will be exposed to a maximum tolerated dose of each drug (as defined in part 1 of the study). During both parts of the study, investigators will carefully characterize any acute and persisting subjective, affective, cognitive, and neural dose-dependent effects for both drugs being evaluated. Much debate exists around the relative potential benefits of micro vs macro-doses for psychedelic compounds. Using a highly controlled approach, the currently planned clinical trial will go some way to answering this important question. Employing an extensive battery of psychological assessment tools, coupled with state-of-the-art functional MRI and EEG the JHU researchers endeavour to develop a more fulsome understanding of how DMT acts in the brain of healthy volunteers; with the ultimate goal of being able to apply this knowledge in tailoring the treatment of serious neuropsychiatric conditions.

This clinical research collaboration builds upon PharmaDrug’s existing strategy of focusing on establishing a better understanding of the basic mechanisms by which DMT exerts its effects in the brain and elsewhere in the body. By supporting world class talent with distinct expertise in early discovery and clinical use the Company will be optimally positioned to identify novel applications for DMT and unlock its full therapeutic potential. The Company intends to become a leader in advancing DMT as a prescription pharmaceutical, and as previously reported, is the first organization to receive orphan drug designation by the U.S. FDA for DMT in the prevention of ischemia-reperfusion injury in patients undergoing solid organ transplantation, which includes the liver, kidney, heart, and lungs. As a further example of PharmaDrug’s commitment to DMT development, the Company recently entered into a sponsored research agreement with the Terasaki Institute to evaluate the potential of novel DMT delivery systems for the treatment of primary open angle glaucoma, one of the leading causes of vision loss worldwide.

Daniel Cohen, CEO of PharmaDrug commented: “We are excited to collaborate and support Dr. Frederick Barrett to better understand DMT and its potential. The JHU Center for Psychedelic and Consciousness Research is a global leader in psychedelics clinical research, and we are very grateful to partner with them to achieve our objectives in expanding our pharmaceutical product pipeline for novel uses and delivery forms of DMT to treat unmet medical needs.”

Under the terms of the agreement, the Company has an exclusive option to obtain worldwide, royalty-bearing commercialization license to all rights, title, and interest that JHU may have or obtain in any invention that results from the clinical study.

About PharmaDrug Inc.

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. The Company owns 80% of Pharmadrug Production GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU. The Company also owns 100% of Super Smart, a Dutch company building a modern adult use psychedelic retail business with an elevated and educational focus. PharmaDrug recently acquired Sairiyo Therapeutics, a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through regulatory and research driven clinical trials.

For further information, please contact:

Daniel Cohen, Chairman and CEO
[email protected]
(647) 202-1824

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential”, “aim” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaDrug Inc. (the “Company”) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of March 31, 2021 (“MD&A”), dated May 31, 2021, which is available on the Company’s profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

References:

1) Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D. Self-blinding citizen science to explore psychedelic microdosing. Elife. 2021 Mar 2;10:e62878. doi: 10.7554/eLife.62878. PMID: 33648632; PMCID: PMC7925122.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.